124 related articles for article (PubMed ID: 22200788)
1. p53 codon 72 polymorphism as a progression index for bladder cancer.
Lin HY; Huang CH; Yu TJ; Wu WJ; Yang MC; Lung FW
Oncol Rep; 2012 Apr; 27(4):1193-9. PubMed ID: 22200788
[TBL] [Abstract][Full Text] [Related]
2. p53 codon 72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in a Taiwanese population: an implication of structural equation modeling to manage the risks of bladder cancer.
Lin HY; Huang CH; Yu TJ; Wu WJ; Yang MC; Lung FW
Urol Int; 2011; 86(3):355-60. PubMed ID: 21346315
[TBL] [Abstract][Full Text] [Related]
3. Association of p53 codon 248 (exon7) with urinary bladder cancer risk in the North Indian population.
Jaiswal PK; Goel A; Mittal RD
Biosci Trends; 2011; 5(5):205-10. PubMed ID: 22101376
[TBL] [Abstract][Full Text] [Related]
4. P53 codon 72 polymorphism in bladder cancer--no evidence of association with increased risk or invasiveness.
Törüner GA; Uçar A; Tez M; Cetinkaya M; Ozen H; Ozçelik T
Urol Res; 2001 Dec; 29(6):393-5. PubMed ID: 11828992
[TBL] [Abstract][Full Text] [Related]
5. Distributions of p53 codon 72 polymorphism in bladder cancer--proline form is prominent in invasive tumor.
Chen WC; Tsai FJ; Wu JY; Wu HC; Lu HF; Li CW
Urol Res; 2000 Oct; 28(5):293-6. PubMed ID: 11127705
[TBL] [Abstract][Full Text] [Related]
6. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
Kawahara T; Kojima T; Kandori S; Kurobe M; Yoshino T; Kimura T; Nagumo Y; Ishituka R; Mitsuzuka K; Narita S; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Miyazaki J; Nishiyama H
PLoS One; 2019; 14(8):e0220173. PubMed ID: 31369573
[TBL] [Abstract][Full Text] [Related]
7. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
Al-Kashwan TA; Houshmand M; Al-Janabi A; Melconian AK; Al-Abbasi D; Al-Musawi MN; Rostami M; Yasseen AA
BMC Res Notes; 2012 Aug; 5():466. PubMed ID: 22929185
[TBL] [Abstract][Full Text] [Related]
8. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese.
Suzuki K; Matsui H; Ohtake N; Nakata S; Takei T; Nakazato H; Okugi H; Koike H; Ono Y; Ito K; Kurokawa K; Yamanaka H
J Biomed Sci; 2003; 10(4):430-5. PubMed ID: 12824702
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospital-based case-control study.
Zhang R; Chen W; Zhang W; Jiang Q; Liu C; Lin Y; Hu Z; Yu S; Xu G
Genet Test Mol Biomarkers; 2011 May; 15(5):337-41. PubMed ID: 21291320
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer.
Li DB; Wei X; Jiang LH; Wang Y; Xu F
Genet Mol Res; 2010 Aug; 9(3):1599-605. PubMed ID: 20730711
[TBL] [Abstract][Full Text] [Related]
11. p53 codon 72 polymorphism and its association with bladder cancer.
Soulitzis N; Sourvinos G; Dokianakis DN; Spandidos DA
Cancer Lett; 2002 May; 179(2):175-83. PubMed ID: 11888672
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide synthase (eNOS4a/b) gene polymorphism is associated with tumor recurrence and progression in superficial bladder cancer cases.
Amasyali AS; Kucukgergin C; Erdem S; Sanli O; Seckin S; Nane I
J Urol; 2012 Dec; 188(6):2398-403. PubMed ID: 23088972
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
14. Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population.
Hosen MB; Salam MA; Islam MF; Hossain A; Hawlader MZ; Kabir Y
Tumour Biol; 2015 Aug; 36(8):6369-74. PubMed ID: 25801242
[TBL] [Abstract][Full Text] [Related]
15. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
[TBL] [Abstract][Full Text] [Related]
17. The role of oncostatin M receptor gene polymorphisms in bladder cancer.
Deng S; He SY; Zhao P; Zhang P
World J Surg Oncol; 2019 Feb; 17(1):30. PubMed ID: 30755233
[TBL] [Abstract][Full Text] [Related]
18. Association of a p53 codon 72 gene polymorphism with environmental factors and risk of lung cancer: a case control study in Mizoram and Manipur, a high incidence region in North East India.
Saikia BJ; Das M; Sharma SK; Sekhon GS; Zomawia E; Singh YM; Mahanta J; Phukan RK
Asian Pac J Cancer Prev; 2014; 15(24):10653-8. PubMed ID: 25605155
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan.
Chen YC; Xu L; Guo YL; Su HJ; Hsueh YM; Smith TJ; Ryan LM; Lee MS; Chaor SC; Lee JY; Christiani DC
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2003 Jan; 38(1):201-11. PubMed ID: 12635827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
